---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000016"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:55:59.343959+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus

## Summary
- Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.
- Venkatesan previously co-founded Alpine Immune Sciences (acquired by Vertex for $4.9B) and served as CEO of Angion Biomedica.
- Dr. Milton Harris departs board effective Feb 11, 2025, becomes Director Emeritus and Chair of Scientific Advisory Board.
- Harris is co-founder, instrumental in POZ Platform; departure not due to any disagreement.

## SEC filing metadata
- accession: 0001708599-25-000016
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/ser-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000016
- JSON: https://secwatch.observer/filing/0001708599-25-000016.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000016.txt

## Key facts
- Executive change
  Dr. Jay Venkatesan was appointed as Director at Serina Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm
- Executive change
  Dr. Milton Harris departed as Director at Serina Therapeutics, Inc..
  - Action: departed
  - Role: Director
  source text: The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.